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ABSTRACT
The increasing prevalence of Alzheimer’s disease (AD) poses a
considerable socio-economic challenge. Decades of experimen-
tal research have not led to the development of effective disease
modifying interventions. A deeper understanding of in vivo
research might provide insights to inform future in vivo research
and clinical trial design. We therefore performed a systematic
review and meta-analysis of interventions tested in transgenic
mouse models of AD. We searched electronically for publica-
tions testing interventions in transgenic models of AD. We
extracted data for outcome, study characteristics and reported
study quality and calculated summary estimates of efﬁcacy using
random effects meta-analysis. We identiﬁed 427 publications
describing 357 interventions in 55 transgenic models, involving
11,118 animals in 838 experiments. Of concern, reported study
quality was relatively low; fewer than one in four publications
reported the blinded assessment of outcome or random alloca-
tion to group and no study reported a sample size calculation.
Additionally, there were few data for any individual
intervention—only 16 interventions had outcomes described in
5 or more publications. Finally, “trim and ﬁll” analyses suggested
one in seven pathological and neurobehavioural experiments
remain unpublished. Given these historical weaknesses in the
in vivo modelling of AD in transgenic animals and the identiﬁed
risks of bias, clinical trials that are based on claims of efﬁcacy in
animals should only proceed after a detailed critical appraisal of
those animal data.
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Introduction
The burden of Alzheimer’s disease (AD) is expected to
rise substantially in the coming years, and the develop-
ment of treatments which might halt or reverse disease
progression is therefore of considerable importance.
Around 5% of AD cases are familial, and the identiﬁcation
of the genetic causes of these has informed the genera-
tion of a number of transgenic mouse lines expressing
mutations known to cause human disease, which have
been used to model aspects of AD. Such models have
become increasingly sophisticated and some transgenic
lines manifest several features of AD including tau neuro-
ﬁbrillary tangles, amyloid plaques and cognitive change.1
One use to which these mice have been put is in
efforts to develop treatments for AD, with over
300 interventions having been tested in the Tg2576
mouse model alone.2 However, efﬁcacy observed in ani-
mal studies has proved to be a poor guide to efﬁcacy in
clinical trials, and a deeper understanding of the use and
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limitations of studies using transgenic mouse models
might increase our understanding of the possible reasons
for this. Systematic review and meta-analysis are useful
tools to assess the internal and external validity of a
research ﬁeld.3–5 Systematic review can provide an unbi-
ased ascertainment of publications in a given area while
meta-analysis allows the calculation of global estimates of
efﬁcacy and of efﬁcacy in sub-groups of studies with
shared characteristics. Reed et al. have previously
reported the use of these techniques on data from their
own laboratory to derive more precise estimates of
change in performance in the Morris water maze
(MWM), and while they did not address issues of internal
or external validity they did demonstrate the feasibility of
this approach.6 In the modelling of other neurological
conditions such as focal cerebral ischaemia, multiple scle-
rosis and Parkinson’s disease, the consistent ﬁnding has
been that publications reporting measures to reduce the
risk of bias give consistently lower estimates of efﬁcacy.3–5
The presumption that these lower estimates of efﬁcacy
were more likely to be accurate led to the development
of guidelines for good laboratory practice7 and informed
the development of the ARRIVE statement.8
Here, we use a similar approach to ascertain the prev-
alence and impact of factors known to increase the risk
of bias in the literature describing the modelling of AD in
animals. We use systematic review to identify relevant
publications and a predeﬁned analysis plan to provide a
systematic description of the published literature report-
ing the testing of interventions in transgenic mouse mod-
els of AD. From these publications, we extracted data for
reported pathological and neurobehavioural outcome
measures to assess the impact on reported efﬁcacy of
study features which might increase the risk of bias and
to make an assessment of the presence and magnitude of
any publication bias.
Methods
We have previously described the CAMARADES AD
dataset, including the search strategy used, criteria for
inclusion and exclusion, data extraction and the data dic-
tionary for that dataset, which is available in Figshare
(http://ﬁgshare.com/articles/Interventions_tested_in_pre
clinical_studies_using_transgenic_mouse_models_of_AD/
1185428). The study protocol, including dates of and
rationale for revisions to that protocol, is also available
(www.camarades.info).
Brieﬂy, we searched Pubmed, EMBASE and ISI Web of
knowledge for studies on transgenic animal models of AD
using the search terms [“targeted deletion” OR “overex-
pression” OR “knock out” OR “vector” OR “transgenic”]
AND [“dementia” OR “tau” OR “mild cognitive impair-
ment” OR “Alzheimer’s disease”] within the limit “ani-
mals”. The searches were taken from 1995 (when the
ﬁrst transgenic AD mouse model was described) and
were conducted in January 2009.
Two reviewers (KE and MM) independently screened
the title and abstract of identiﬁed publications. Studies
were included if they reported the testing of an interven-
tion in any amyloid, tau or presenilin-based transgenic
mouse model of AD. We excluded studies using mice
with additional genetic manipulations (e.g. COX-2 knock-
out). We excluded publications without an appropriate
control and those using combination therapies. For stud-
ies reporting active immunization using amyloid beta pep-
tides, we extracted data on the speciﬁc fragments of Aβ
used and did not examine adjuvants, modiﬁcations or
vectors in further detail.
D A T A E X T R A C T I O N
We included studies where outcomes were reported as
changes in pathology or neurobehaviour. For pathological
outcomes, we included data for plaque burden, cellular
inﬁltration, neurodegeneration, and the abundance of
amyloid beta 40, amyloid beta 42 and tau. For plaque bur-
den, we included all related outcomes such as plaque
number, plaque density and plaque area. We limited the
analysis to plaques identiﬁed by immunohistochemistry to
reduce the possibility of intra-staining variation and to
minimize aggregation bias attributed to alternative staining
techniques. To improve the speciﬁcity of plaque burden
analyses, we focused only on extracellular plaque burden.
Outcomes measuring tau included both overall reduc-
tions in tau and reductions in phosphorylation status, and
for neurodegeneration, we included both direct measures
of neuronal loss (such as cell counting or synapse density)
and indirect measures such as caspase 3 activation.
For all neurobehavioural outcomes except the acquisi-
tion phase of the MWM, we only included data for the
last time point. For the acquisition phase of the MWM,
we extracted data for all time points provided that the
position of the platform had remained constant. For the
probe phase of the MWM, we did not include data for
reversal task behaviour and for time in opposite or adja-
cent quadrants.
To assess factors relating to risk of bias and study quality,
we recorded the reporting of (1) random allocation to
group, (2) blinded assessment of outcome, (3) sample size
calculation, (4) compliance with animal welfare legislation
and (5) a statement declaring a possible conﬂict of interest.
For the purposes of analysis, we grouped transgenic
mice into six broad classiﬁcations: (1) amyloid precursor
protein (APP) mutations (e.g. APPSwe or APPSwe/Ind),
(2) Presenilin 1 mutations (e.g. PS1L235P or PS1M146L),
(3) tau mutations (e.g. T44 or tgP301L), (4) APP, PS1 or
PS2 mutations, (5) 3xTgAD0 (those with mutations in
APP, PS1 and tau (e.g. APPSwe/PS1M146V/tauP301L) and
(6) other (AD11, Tg13592 and Nse/ps2m transgenic
mice). For active immunization by fragments of amyloid
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beta, we classed interventions by the fragment of amyloid
used only.
We assessed the potential impact of publication bias
using Egger regression, funnel plot asymmetry and “trim
and ﬁll” techniques. We ﬁrst derived overall estimates of
the impact on pathological and neurobehavioural out-
comes. To address the possibility that observed small
study effects might be because of systematic differences
between types of study (for instance, one outcome meas-
ure detecting large effects but with large variance and
another showing smaller effects with smaller variance),
we conducted sensitivity analyses using subsets of data-
sets aggregated by outcome measures, transgenic model
groups and brain regions (not shown).
S T A T I S T I C S
The details of and the rationale for the statistical
approach taken is described in detail elsewhere.9 Brieﬂy,
we deﬁned a comparison as an outcome measured in a
group of treated transgenic animals compared with that
in untreated control transgenic animals. For each com-
parison, we extracted data for numbers per group, mean
outcome and variance. Where a single control group
served multiple experimental groups, we corrected the
weighting given to that group in the meta-analysis by
dividing the number of animals in the control group by
the number of treatment groups served. For each com-
parison, we calculated a standardized mean difference
effect size. We aggregated individual effect sizes using
DerSimonian and Laird random effects meta-analysis.10
To examine any impact of randomization and blinding
on the effect sizes estimated, we ﬁrst calculated summary
estimates of efﬁcacy for each outcome using DerSimmo-
nian and Laird random effects standardized mean differ-
ence meta-analysis. For each of randomization and
blinding and for each outcome measure, we calculated
efﬁcacy in studies at high and low risk of bias, and then,
calculated an effect size for the difference between these.
We then pooled these using random effects meta-analysis
to give an estimate of the overall impact of these two
potential sources of bias. We then used stratiﬁed meta-
analysis to test whether this impact was different for
pathological or behavioural outcomes.
All stratiﬁed analyses were pre-speciﬁed and a subsam-
ple of the dataset (10%) was crosschecked by a blinded
reviewer for consistency. Signiﬁcant differences between
n groups were assessed by partitioning heterogeneity
using the χ2 statistic with n – 1 degrees of freedom. We
adjusted our critical signiﬁcance threshold to account for
the number of comparisons using a Holm–Bonferroni
correction (p < 0.025 for overall estimates, <0.017 for
individual neurobehavioural outcomes and <0.009 for
pathological outcomes).
Results
We identiﬁed 8,360 publications of which 427 met our
inclusion criteria (see Figure 1 for ﬂow diagram and
Figure 2A for year by year breakdown). These reported
the testing of 357 different treatment strategies in 55 differ-
ent transgenic models (Table 1). Pathological or neurobeha-
vioural outcomes were reported from 838 experiments
involving 11,118 animals. APP transgenic mice were used in
289 of 427 (68%) publications (Figure 2B) including the
most commonly reported mouse, the Tg2576 mouse which
was used in 149 publications. 8.9% (38/427) of publications
reported using more than one transgenic mouse model.
Pathological outcomes were reported in 302 publica-
tions. Two hundred and twenty-eight publications
reported changes in plaque burden, determined using
immunohistochemistry in 378 experiments described in
198 publications. Changes in amyloid beta 40 and amyloid
beta 42 were reported in 164 (388 experiments) and
176 (389 experiments) publications, respectively. Changes
8360 publications identified 
from systematic search 
7933 publications 
excluded 
122 publications
neurobehavioral outcomes 
302 publications
pathological outcomes 
397 Full publications and 30 
abstracts 
Outcome 
   
• Plaque burden 
• Amyloid beta 42 
• Amyloid beta 40 
• Cellular infiltrates 
• Neurodegeneration 
• Tau 
  
Outcome 
 
• MWM 
• RAWM 
• Fear conditioning 
• T-maze/Y-maze 
• NORT 
• Open field test 
  
#pub 
 
228 
176 
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60 
41 
38 
 
#pub 
 
76 
22 
19 
19 
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15 
 
Figure 1. Systematic search process alongside the number of
publications reporting speciﬁc pathological and behavioural
outcomes. From the included 427 publications (397 full
publications and 30 abstracts), we identiﬁed a number of main
outcomes including, plaque burden, amyloid beta 40, amyloid
beta 42, tau, neurodegeneration, cell inﬁltrates and
neurobehaviour and the number of publications is shown in the
bottom two boxes. As each publication can have more than
one outcome, the numbers in the bottom two boxes do not
necessarily add up to the numbers above. MWM, Morris water
maze; RAWM, radial arm water maze; NORT, novel object
recognition test.
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in tau were reported in 38 publications (84 experiments)
and measures of neurodegeneration were reported in
41 publications (64 experiments). Sixty publications
(89 experiments) reported changes in the abundance of cel-
lular inﬁltrates. Overall, pathological outcome was improved
by 0.78 SD (95% conﬁdence interval [CI] 0.71–0.85,
p < 0.005) although as anticipated there was substantial het-
erogeneity between studies (χ2 = 4,504, I2 = 83.9%).
Neurobehavioural outcomes were reported in
122 publications; 76 publications reported outcomes
from the MWM of which 130 experiments reported data
from the acquisition phase and 113 reported data from
the probe phase. Outcomes from the radial arm water
maze were reported in 22 publications (41 experiments),
from fear conditioning in 19 (45 experiments), from the
T or Y maze in 19 (28 experiments) and from the novel
object recognition task in 15 (25 experiments). Data from
the open ﬁeld test were reported in 15 publications invol-
ving 24 experiments. Performance in wild-type mice was
reported in 18 experiments; in transgenic mice mobility
in the open ﬁeld was higher than wild type in 11 experi-
ments (including 10 of 11 studies using 3xTgAD lines and
one using APP lines) and lower than wild type in 7 experi-
ments (including 4 of 7 studies using APPPS lines, 3 of
7 using APPS lines) (Figure S1, Supporting Information).
These data were not analysed further. Overall, neurobe-
havioural outcome was improved by 0.61 SD (95% CI
0.54–0.69, p < 0.005, χ2 = 586.2, I2 = 56.0).
M E T H O D O L O G I C A L V A R I A T I O N
Age of animals used and interventions tested
Across all outcomes the median age at which treatment
was begun was 168 days (IQR[inter-quartile-range]
84–311) and the median age at which outcome was
assessed was 308 days (IQR 175–420). We identiﬁed
Table 1. Transgenic mouse model use: our systematic search
identiﬁed the description of 55 different transgenic models
which were categorized according to transgenic model groups;
APP, PS1, tau, APPPS1, 3xTgAD, unknown and other. Numbers
represent the number of publications
Transgenic model group Transgene Total
3xTgAD 3xTgAD 28
APP Tg2576 149
TgCRND8 30
APPV717F 27
APPswe 19
APP751lon/swe 15
J20 APPSWE/IND 15
APP23 14
APPlon 12
APP 4
APPlon/swe 4
APP-YAC 2
TG-SwDI 2
APP51/16 1
APP695 1
APP695lon/swe 1
APParc (E22G) 1
APPV717F (APOE KO) 1
APPV717I 1
APPV717I-CT100 1
CamKII ttA × tet APPswe/ind 1
tgNORBA 1
APPPS APPswe/PS1dE9 41
APPswe/PS1M146L 23
APPswe/PS1 7
APPswe/PS1A246E 5
APPswe/PS1M146V 5
APPV717I/PS1A246E 4
APPPS1 3
APPswe/PS1L166P 2
APPswe/PS2N141I 2
APPV717F/PS1M146L 2
APP23/PS45 1
APP24 1
APP695K594N,M595L/PS1de9 1
APPswe/PS1P246L 1
Other AD11 4
Nse/ps2m 1
Tg13592 1
PS1 PS1 1
PS1dE9 1
PS1-L235P 1
(continued overleaf )
Table 1. (continued)
Transgenic model group Transgene Total
PS1M146L 2
PS1M146V 2
tau tgP301L 6
T44 4
p25 2
tau V337M 2
GSK-3/VLW 1
GSK3betaS9A 1
NFT P301S/K257T 1
NSE/APPsw 1
P301S/K257T 1
pNSE/htau23 1
Unknown Unknown 7
2016 | Volume 3 | Issue 1 | e00015
Page 15
Critical review of animal studies in dementia
357 different interventions, but few were tested exten-
sively, only 16 being reported in ﬁve or more publica-
tions (Figure 3). We chose not to categorize
interventions by drug class or mode of action because we
were not conﬁdent of any criteria with which we could
reliably base such a categorization.
Pathological experiments
For all outcome measures, there was considerable varia-
tion in the way in which that outcome was measured. For
instance, changes in tau were reported in 38 publications
representing 84 experiments (involving 984 animals).
Changes in both the abundance and the phosphorylation
state of tau were reported from 28 experiments, with
changes in abundance alone reported in 25 experiments
and of phosphorylation alone in 31 experiments. Changes
in tau phosphorylation were reported from nine different
phosphorylation sites.
Neurobehavioural experiments
The most commonly used neurobehavioural test was the
MWM (83 publications). These reported data from
130 experiments involving 2,151 animals tested during
the acquisition phase and 113 experiments involving
2,018 animals tested during the probe phase. Again, there
was substantial variation in the details of how these
experiments were performed; water temperature ranged
from 16C to 28C, the size of the pool varied from
85 to 200 cm, the number of trials per day ranged from
2 to 12 and number of training days ranged from 1 to 15.
Many publications did not give details of these variables
(Figure 4).
From the acquisition phase, seven different outcomes
were reported; “latency” (107 experiments), “path
length” (57 experiments), “trials to criterion” (2 publica-
tions), “search error” (2 experiments) “cumulative dis-
tance to platform” (1 experiment) “time in outer zone”
(1 experiment) and “difference in path length” (1 experi-
ment). For the probe phase there was if anything greater
variability in its use; 12 principal methods were used to
measure efﬁcacy, and within the 57 studies which used
the probe phase of the MWM there were 59 different
approaches used to demonstrate efﬁcacy (see Table S1).
S T U D Y Q U A L I T Y
Measures associated with risk of bias and study quality
were reported in few publications, and the median study
Figure 2. Number of publications by year and frequency of transgenic model groups. Since 1998, there has been an increase in the
number of publications per year until the search was conducted (A), for transgenic mouse model groups, we categorized transgenic
mouse models into the transgenic model group used which included; tau, PS, amyloid precursor protein (APP), 3xTgAD, other and
unknown transgenic groups (B). See methods for details of these transgenic model groups.
Figure 3. Interventions with outcomes reported in ﬁve or more
publications. The 16 most commonly tested interventions where
outcomes were reported and the number of publications they
feature in. A beta 1-42: active immunization using amyloid beta 1-
42, A beta 1-15: active immunization using amyloid beta 1-15, Env.
Enrichment, environmental enrichment; LPS, lipopolysaccharide.
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met only one of a possible ﬁve study quality checklist
items (IQR 0–2). Random allocation to group was
reported by 67 of 427 publications (16%), blinded assess-
ment of outcome by 95 (22%), a statement of potential
conﬂict of interest by 54 (13%), compliance with animal
welfare regulations by 239 (56%); and no publication
reported a sample size calculation. The lack of sample
size calculation was accompanied by small group sizes;
for neurobehavioural outcomes, the median group size
was 7 (IQR 7–14) in the control group and 9 (IQR 6–12)
in the treatment group; and for pathological outcomes,
7 (IQR 5–9) and 7 (IQR 5–10), respectively.
Overall, stratifying pathological outcomes by aggregate
study quality accounted for a signiﬁcant proportion of the
observed heterogeneity (χ2 = 142, 725 observations,
p < 0.03, Figure 4, Table S2); however, there was no clear
relationship between study quality and effect size. Simi-
larly, stratifying neurobehavioral summary data accounted
for a signiﬁcant proportion of the observed heterogeneity
but a clear relationship could not be deﬁned (χ2 = 10.7,
p < 0.03, Figure 4, 259 observations, Table S2).
We identiﬁed four individual pathological outcomes
where stratiﬁcation by aggregate study quality explained
a signiﬁcant proportion of the observed heterogeneity.
In studies reporting a change in plaque burden, amyloid
beta 42, tau, and cell inﬁltrates, the number of check-
list items scored accounted for a signiﬁcant proportion
of between study heterogeneity (χ2 = 110, 23.3, 13.4
and 129, respectively, df = 4, p < 0.009, Figure 5,
Table S2).
Overall, reported efﬁcacy was 3.4% higher in non-
randomized studies (relative difference, 95% CI 1.8–5.0%,
see Figure S2). There was an apparent difference between
pathological outcomes (9.0% lower, 95% CI -11.8 to -6.0%)
and behavioural outcomes (28% higher, 95% CI
26.1–30.7%), but partitioning by the type of outcome did
not explain a signiﬁcant proportion of the observed hetero-
geneity (p = 0.053). Overall, reported efﬁcacy was 5.8%
higher in non-blinded studies (95% CI 2.8–8.8%; Figure S3);
for pathological outcomes efﬁcacy was 2.6% higher (95%
CI −1.5% to 6.7%) and for behavioural outcomes efﬁcacy
was 13.1% higher (6.6–19.6%); partitioning heterogeneity
Figure 4. Variation in Morris water maze experimental design. The use of the Morris water maze (MWM) varied considerably with
respect the size of the pool used (A), water temperature (B), the number of training trials per day (C) and number of days
trained (D).
2016 | Volume 3 | Issue 1 | e00015
Page 17
Critical review of animal studies in dementia
by the type of outcome did explain a signiﬁcant proportion
of the observed heterogeneity (p = 0.014).
P U B L I C A T I O N B I A S
To investigate publication bias, we assessed all pathologi-
cal outcomes using Egger regression, which did suggest
missing studies (Figure 6A, see Table 2 for overview).
Funnel plot asymmetry was also consistent with publica-
tion bias (Figure 6B). Trim and ﬁll suggested that
observed efﬁcacy of 0.749 SD (95% CI 0.702–0.796,
2,517 experiments) was reduced to 0.419 SD
(0.367–0.470) after the inclusion of 483 imputed missing
studies (Figure 6C). For neurobehavioral outcomes, we
again found evidence of publication bias with both Egger
regression and funnel plot asymmetry (Figure 6D and E).
Trim and ﬁll suggested a baseline efﬁcacy of 0.600 (0.537-
0.664), 561 experiments) which was reduced to 0.400
(0.329 to 0.471) after the inclusion of 98 imputed missing
studies (Figure 6F, Table 2).
To ensure our ﬁndings of publication bias were not
because of differences between outcomes, transgenic
model groups or brain regions (wherever appropriate), we
performed sensitivity analysis in strata of speciﬁc outcomes
measures, transgenic model groups and brain areas and
found persisting evidence of publication bias in all analyses
save trim and ﬁll analysis of cellular inﬁltrates outcomes.
Figure 5. Impact of study quality items across all reported outcomes. We stratiﬁed outcomes to identify whether there was an
association between effect size and overall study quality across (A) plaque burden, (B) amyloid beta 40, (C) amyloid beta
42, (D) tau, (E) cellular inﬁltrates (F) neurodegeneration, (G) acquisition phase of the Morris water maze, (H) probe phase of the
Morris water maze and (I) non-Morris water maze-based behavioural paradigms. For each outcome, the horizontal grey bar
represents 95% conﬁdence interval (CI) of the global estimate, vertical error bars represent 95% CI of summary estimates and bar
width represents the log of the number of animals.
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Figure 6. Publication bias assessment across pathological and behavioural outcomes: summary data for pathological and
neurobehavioral outcomes. Pathological outcomes are assessed by (A) Egger regression, (B) funnel plot asymmetry and (C) Trim
and ﬁll techniques (missing studies shown in red). Likewise neurobehavioural data are assessed through Egger regression (D), funnel
plot asymmetry and (E) Trim and ﬁll techniques (F).
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Table 2. Publication bias analyses: summary table of assessing pathological outcomes for the presence of publication bias through
Egger regression, Funnel plot asymmetry and Trim and ﬁll techniques. Where Trim and ﬁll identiﬁed publication bias, both the
unadjusted and adjusted estimates of efﬁcacy are given alongside the percentage of experiments which are hypothesized missing.
Outcome measure
Publication bias
identiﬁed from:
“Trim and Fill” global estimate
(standard deviations [95%
conﬁdence interval] and N) Number
missing
Global estimate
Egger
Funnel
plotting Unadjusted Adjusted (%)
Absolute
change (SD)
Relative
change (%)
Plaque burden Y Y 0.999 0.61
(antibody stained) (0.905–1.093) (0.508–0.712) 154 0.389 63.8
632 786 (−19.6)
Amyloid beta 40 Y Y 0.635 0.321
(0.547–0.724) (0.221–0.421) 124 0.314 97.8
625 749 (−16.6)
Amyloid beta 42 Y Y 0.706 0.351
(0.616–0.796) (0.250–0.452) 136 0.355 101.1
632 768 (−17.7)
NFT Y Y 0.533 0.285
(0.400–0.666) (0.141–0.430) 43 0.248 87
273 316 (−13.6)
Cell inﬁltrates Y N 0.561 0.561
(0.367–0.755) (0.367–0.755) 0 0 0%
222 222 0
Neurodegeneration Y Y 0.962 0.764
(0.784–1.140) (0.566–0.961) 17 0.198 25.9
133 150 (−11.3)
Pathology Y Y 0.749 0.419
0.33 78.8(0.702–0.796) (0.367–0.470) 483
2,517 3000 (−16.1)
Acquisition phase of MWM Y Y 0.486 0.349
(0.402–0.570) (0.260–0.438) 32 0.137 39.3
164 196 (−16.3)
Probe phase of MWM Y Y 0.623 0.4
0.223(0.503–0.744) (0.262–0.539) 32 55.8
212 244 (−13)
Fear conditioning Y Y 0.693 0.503
(0.495–0.890) (0.297–0.709) 10 0.19 37.8
60 70 (−14.3)
Radial arm water maze Y Y 0.804 0.507
(0.585–1.024) (0.279–0.735) 16 0.297 58.6
53 69 (−23.1)
T and Y maze Y Y 0.382 0.299
(0.166–0.597 (0.068–0.530) 3 0.083 27.8
42 45 (−6.7)
Novel object recognition task Y Y 0.904 0.629
(0.618–1.190) (0.300–0.959) 6 0.275 43.7
30 36 (−16.7)
Neurobehaviour Y Y 0.6 0.4 98 0.2 50
(0.537–0.664) (0.329–0.471) (−14.9)
561 659
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Discussion
In this systematic review, we identiﬁed 427 publications
reporting data from 55 different transgenic mouse mod-
els testing 357 separate intervention strategies. Measures
to avoid bias such as blinding and randomization were
rarely reported, and the absence of sample size calcula-
tions was accompanied by low group sizes across all
reported data. Only 16 of the 357 interventions were
tested in more than 4 publications and trim and ﬁll analy-
sis suggested that 1 in 7 pathological and neurobeha-
vioural remain unpublished. Collectively, these ﬁndings
provide further insight into plausible reasons for transla-
tional failure.
L I M I T A T I O N S
There are a number of limitations to this work. For the
analyses conducted, we only include data in the public
domain, and we have shown evidence of a signiﬁcant pub-
lication bias. However, this is likely to be less distorting
that is the case for narrative reviews. Secondly, this is in
essence an observational study, and the differences
observed do not conﬁrm causal relationships; our ﬁnd-
ings should be considered hypothesis generating only.
As with individual studies using transgenic animals
some ﬁndings may be because of speciﬁc mutations, zyg-
osity, promoter or background strain, but the relative
consistency of ﬁndings between different mouse strains
and different laboratories suggest that it is possible to
generalize from ﬁndings beyond the speciﬁc details of
individual experiments. Further, for the majority of our
neurobehavioural data, our restriction to limit this to the
last time point available would not have detected a tran-
sient improvement in function; however, we took the
view that the most clinically relevant outcome was the
longest term outcome available.
We have assessed the risks of bias on the basis of
study reports, and it may be that measures to reduce
the risk of bias were taken but not reported. However,
since the assessment of risk of bias is a central compo-
nent of critical reading of the scientiﬁc literature, publi-
cations which do not report measures to reduce the
risk of bias should, in our view, be considered to be at
higher risk of bias than those which do report such
measures. Such issues are widespread: recent evidence
has highlighted that measures to avoid bias in published
literature are independent of the journal of
publication.11
The search was conducted in 2009, and so cannot be
taken to be representative of current AD modelling in
either the prevalence or impact of biases because of
study design or publication bias. Indeed, there is some
evidence11 of improvement in reporting across the life
sciences, perhaps because of, for example, the ARRIVE
and Landis guidelines. However, at worse this gives us a
baseline against which to measure such improvements,
and we provide further motivation, if any is needed, for
continuing efforts to improve the reporting, and perhaps
the conduct, or in vivo research in AD as elsewhere.
Finally, selecting primary outcome measures on the
basis of their prevalence in the literature could encourage
analysis on the basis of those outcomes favoured by the
community, which might not be the most clinically rele-
vant outcomes. However, in the absence of consensus to
the most relevant outcomes in animals, we believe that
our approach is reasonable.
I N T E R N A L V A L I D I T Y
Notwithstanding these limitations, we have shown that
the reporting of fundamental study quality items12 was
relatively low. Overall, both randomization and blinding
were associated with smaller effect sizes. Behavioural
outcome measures appeared to be more susceptible to
these biases than did pathological outcome measures, and
for the blinded assessment of outcome this reached sta-
tistical signiﬁcance. Interestingly, for pathological out-
comes, randomization was associated with larger
estimates of efﬁcacy; we cannot explain this observation.
It is also interesting to note that the impact of blinding
and randomization appears to be smaller than in animal
models of other diseases.13
The reporting of a power calculation is important both
to reassure the reader that group size has not been
inﬂated while the experiment was in progress and that
the study was adequately powered to conﬁrm or refute a
biologically important effect. We and others have pre-
sented evidence that animal studies modelling multiple
sclerosis and AD5,14 are usually underpowered, and
against this background it is troubling that not one of the
427 studies reported a sample size calculation, and that
the sample sizes were generally small.
E X T E R N A L V A L I D I T Y
A crucial issue in the modelling of AD is the stage of dis-
ease at which treatment is initiated;2,14 our data suggest
that most interventions are initiated relatively early in the
mouse lifespan, being a median of 168 days (IQR 84–308)
for pathological outcomes and 140 days (IQR 84–280)
for neurobehavioural outcomes.
We found remarkable variation in experimental
approaches used and outcome measures reported. This
may be a function of reporting bias, with only those
outcomes giving statistically signiﬁcant ﬁndings or those
consistent with the hypothesis under investigation being
reported. For the probe phase of the MWM (where we
identiﬁed 12 different outcome measures) previous
work has suggested that the most sensitive outcome
measure is the mean proximity to the former platform
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location15 but this was not commonly used. Pathological
outcomes were reported twice as frequently as neuro-
behavioural outcomes although it should be noted that
this may be partly explained by limitations of the animal
models themselves. Of those reporting pathological
outcomes only 1 in 10 reported changes in tau or
neurodegeneration—both considered important features
of human disease. Further insight into trial design may
be provided if we can extend this work to identify those
pathological outcomes which correlate best with
improvements in neurobehavioural outcome in animals,
as these may give a better indication of potential efﬁcacy
in human studies.
P U B L I C A T I O N B I A S
Our publication bias analyses suggested that there is a
large body of missing neutral or negative studies, and
accounting for these led to substantial downward revi-
sions in our estimates of pathological and neurobeha-
vioural efﬁcacy. This is of concern because it suggests
that clinical trials may be based on incomplete data, and
that there may be unnecessary repetition of animal
experiments at the preclinical trial stage.
Conclusions
There is a substantial literature describing the efﬁcacy of
various interventions in transgenic models of AD. We
found that preclinical studies are characteristically diverse
and few studies report fundamental study quality items
(e.g. blinding, randomization); risk of bias does indeed
impact on the observed efﬁcacy; and an extensive publi-
cation bias is present across the transgenic mouse model
literature. As a scientiﬁc community, collectively addres-
sing these components of research design would
decrease the risk of overstating efﬁcacy from experi-
ments conducted in animal models of AD. Collectively,
these ﬁndings conﬁrm that we cannot take evidence from
preclinical trials at face value, and further demonstrate
the utility of systematic review and meta-analysis.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Construct validity issues in the use of the open
ﬁeld test: for outcomes from the open ﬁeld test, the pres-
ence of a transgene was associated with both an increase
and decrease in ambulation. Data were “normalised”
whereby control transgenic outcomes equated to 100%.
Error bars represent the standard deviation of each esti-
mate and colours represents transgenic model group used.
Figure S2. Risk of bias for randomization: overstatement
of efﬁcacy in studies which did not report random alloca-
tion to group. Nft, neuroﬁbrillary tangles; inf, cellular
inﬁltrates; Neurod, neurodegeneration.
Figure S3. Risk of bias for blinding: overstatement of efﬁ-
cacy in studies which did not report blinding their assess-
ment of outcome. Nft, neuroﬁbrillary tangles; inf, cellular
inﬁltrates; Neurod, neurodegeneration.
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Table S1. Probe phase of the Morris water maze. Twelve
principal methods were used to assess Morris water
maze probe performance. Within these assessments
studies varied by whether they; trained the mice to crite-
rion, preformed multiple trials, assessed probe perfor-
mance less than (<24) or greater than (>24) 24 hours
after training, and the total number of seconds.
Table S2. Impact on overall quality on observed effect
size: we stratiﬁed outcomes to identify whether there
was an association between effect size and overall study
quality score. For each outcome, summary estimates are
provided for effect size, 95% conﬁdence limits. Results
are signiﬁcant where stratiﬁcation accounted for a signiﬁ-
cant proportion of the observed heterogeneity (*).
Table S3. Impact of blinding and randomization: we strati-
ﬁed outcomes to identify whether there was an associa-
tion between effect size and blinding or randomization.
For each outcome, summary estimates are provided for
effect size, 95% conﬁdence interval. Results are signiﬁcant
where stratiﬁcation accounted for a signiﬁcant propor-
tion of the observed heterogeneity.
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